Janux T细胞接合器数据导致股价下跌,但分析师仍看好其成为同类最佳潜力。
Janux T-cell engager data sink stock, but analysts still see best-in-class potential
生物技术与制药领域的最新动态
Janux T-cell engager data sink stock, but analysts still see best-in-class potential
FDA issues draft guidance to reduce primate testing for certain antibodies
Boston Scientific claims European approval for Farapoint focal pulsed field ablation catheter
CDER head Richard Pazdur set to retire shortly after appointment
FDA to remove some monkey testing from monoclonal antibody development
Richard Pazdur, FDA drug czar, to retire from agency
Thermo Fisher Scientific (TMO) Stock on December 2, 2025: Price Action, HSBC Upgrade, New Debt Deal and 2026–2030 Forecasts - ts2.tech
Tech emerges as a new frontier for digital therapeutics
FDA details plan to scale back animal tests for some antibody drugs
Hightide’s HTD-1801 outperforms Farxiga in type 2 diabetes
Subcutaneous biologics maker Bao Pharma prices $128M IPO
ARCH, Parker Institute build next big oncology bet with suite of programs and startup acquisition
Top drug regulator Rick Pazdur plans to leave FDA
An archaeal transcription factor bridges prokaryotic and eukaryotic regulatory paradigms
Imvax takes brain cancer cell therapy to FDA, betting survival hit will overshadow primary miss
Tiziana to spin out IL-6 drug into new company, citing Big Pharma's interest in modality
Novocure promotes new CEO, replacing current chief after less than a year
Roche's point-of-care whooping cough test greenlighted in US, Europe as cases surge
News in brief
Morgan Stanley Initiates Coverage on Agilent Technologies (A) wi - GuruFocus